The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2016 | Phase 1 study of anti-PD-L1 durvalumab plus gefitinib in TKI-naïve patients with EGFR-mutant NSCLC
At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 13–16 April 2016, Don Gibbons, MD, PhD, from The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a phase 1 expansion study evaluating the efficacy, safety and tolerability of durvalumab, a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib for tyrosine kinase inhibitor-naïve patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC).
